 Moleculin Biotech, Inc., Nasdaq: MBRX Moleculin or the Company, a clinical stage pharmaceutical company with a broad portfolio of drug candidates, today announced that it has submitted requests to Polish regulatory authorities for approval to open two additional clinical sites for its Phase 12 clinical study of Annamycin for the treatment of acute myeloid leukemia AML. 